Coloplast A/S/€COLOB
1D1W1MYTD1Y5YMAX
Capital at risk
About Coloplast A/S
Coloplast A/S is a Danish multinational company that specializes in the development and manufacture of medical devices and services. The company's core business operates within the healthcare sector, offering products and services that focus on ostomy care, urology, continence care, and wound and skin care. Founded in 1957 and headquartered in Humlebæk, Denmark, Coloplast has established a strong presence in numerous countries, serving healthcare professionals and patients around the globe. Its strategic positioning is supported by a commitment to innovation and close collaboration with healthcare professionals to ensure the efficacy and safety of its offerings. Coloplast's competitive strengths derive from its comprehensive product portfolio and strong expertise in chronic care solutions.
- Ticker
- €COLOB
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 17,213
- Headquarters
- Humlebæk, Denmark
- Website
- www.coloplast.com
Coloplast A/S Metrics
BasicAdvanced
€13B
35.44
€1.64
0.55
€3.08
5.30%
Price and volume
Market cap
€13B
Beta
0.55
52-week high
€84.74
52-week low
€49.60
Average daily volume
323K
Dividend rate
€3.08
Financial strength
Current ratio
1.561
Quick ratio
0.883
Long term debt to equity
156.535
Total debt to equity
178.073
Dividend payout ratio (TTM)
187.59%
Interest coverage (TTM)
11.52%
Profitability
EBITDA (TTM)
1,153.766
Gross margin (TTM)
67.23%
Net profit margin (TTM)
9.71%
Operating margin (TTM)
26.98%
Effective tax rate (TTM)
30.51%
Revenue per employee (TTM)
€220,720
Management effectiveness
Return on assets (TTM)
10.12%
Return on equity (TTM)
18.53%
Valuation
Price to earnings (TTM)
35.443
Price to revenue (TTM)
3.441
Price to book
7.29
Price to tangible book (TTM)
-6.98
Price to free cash flow (TTM)
15.983
Free cash flow yield (TTM)
6.26%
Free cash flow per share (TTM)
3.637
Dividend yield (TTM)
5.30%
Growth
Revenue change (TTM)
2.06%
Earnings per share change (TTM)
-32.17%
3-year revenue growth (CAGR)
5.34%
10-year revenue growth (CAGR)
6.92%
3-year earnings per share growth (CAGR)
-18.35%
10-year earnings per share growth (CAGR)
7.26%
3-year dividend per share growth (CAGR)
4.77%
10-year dividend per share growth (CAGR)
11.14%
Bulls say / Bears say
The FDA approved Coloplast’s next-generation Titan Prime inflatable penile prosthesis in June 2026, expanding the company’s Interventional Urology portfolio in the U.S. and addressing an estimated 30 million men with erectile dysfunction (Reuters)
Coloplast’s CFO expects the Kerecis wound-care unit to return to growth from January 2027 after current reimbursement headwinds, suggesting the recent impairment may prove a temporary setback (Reuters)
Denmark’s Coloplast reported Q2 organic revenue growth of 6%, driven by strong momentum in its Interventional Urology segment, highlighting the resilience of its core franchises despite currency headwinds (Reuters)
As a result of slower-than-anticipated market recovery in the outpatient setting, Coloplast recognised a goodwill impairment loss of DKK 3.0 billion against its wound-care subsidiary Kerecis, cutting its carrying value to around DKK 6 billion (Reuters)
The outpatient segment of Kerecis “has basically collapsed” since U.S. Medicare reimbursement changes took effect, according to CFO Anders Lonning-Skovgaard, underscoring persistent headwinds in the wound-care business (Reuters)
On April 23, 2026, management lowered full-year guidance, cutting organic revenue growth to 5–6% (from roughly 7%) and adjusted EBIT growth to around 5% (from 7%), reflecting a more cautious outlook for its skin substitutes and broader chronic care segments (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Upcoming events
No upcoming events
Funds containing Coloplast A/S
AllGBPEURUSD
Fund name | Fund size | €COLOB weighting |
|---|---|---|
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.13% |
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 0.08% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 0.08% |
Vanguard FTSE Developed Europe£VEUA | £2.6B | 0.07% |
Vanguard FTSE Developed Europe€VWCG | €3.1B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.